Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Terminated 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 1Neoplasm Metastasis 1

Interventions

pembrolizumab 185Carboplatin 131Paclitaxel 123Gemcitabine 122Docetaxel 97Cyclophosphamide 89Nivolumab 88Cisplatin 87Rituximab 71Dexamethasone 68Pemetrexed 65Bevacizumab 65Capecitabine 60atezolizumab 55fludarabine 49Fluorouracil 49Azacitidine 49130-nm albumin-bound paclitaxel 43Irinotecan 42venetoclax 41Trastuzumab 41Cetuximab 40Leucovorin 37Ipilimumab 36Erlotinib Hydrochloride 35Oxaliplatin 32Fulvestrant 32Cytarabine 32avelumab 31Albumin-Bound Paclitaxel 31

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × INDUSTRY × ferumoxtran-10 × Clear all
NCT04261777 2026-04-28

Ferumoxtran-10-enhanced MRI in Prostate Cancer Patients

Saving Patients' Lives Medical B.V.

Phase 3 Terminated
172 enrolled
Genitourinary

Neoplasm Metastasis, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡